EUVIMEDEUVIMED entdecken
Open Access

Bortezomib With High-dose Melphalan Conditioning Regimen in Newly Diagnosed Multiple Myeloma Patients: Long-term Follow-up

Risa Nishiyama, Toshiya Kagoo, Hironori Ueno, Akihiro Yokoyama

In Vivo · 2025

DOI: 10.21873/invivo.13833 ↗

Kurz gefasst

Fachartikel in der Zeitschrift In Vivo, 2025. Verfasst von Risa Nishiyama und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Internal Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan risanishiyama2353@gmail.co…. Hauptthemen laut MEDLINE: Multiple Myeloma, Bortezomib, Melphalan, Transplantation Conditioning. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaBortezomibMelphalanTransplantation ConditioningTransplantation, AutologousAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleMiddle AgedFollow-Up StudiesAgedAdultRetrospective StudiesHematopoietic Stem Cell TransplantationTreatment OutcomeKaplan-Meier Estimate

Stichwörter der Autor:innen

Multiple myelomaautologous stem cell transplantationbortezomibhigh-dose melphalantransplant eligible

Substanzen

BortezomibMelphalan

Autor:innen und Institutionen

  • Division of Hematology, Department of Internal Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan risanishiyama2353@gmail.com.
  • Division of Hematology, Department of Internal Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.

Zitieren

APA

Nishiyama, R., Kagoo, T., Ueno, H., & Yokoyama, A. (2025). Bortezomib With High-dose Melphalan Conditioning Regimen in Newly Diagnosed Multiple Myeloma Patients: Long-term Follow-up. In Vivo. https://doi.org/10.21873/invivo.13833

Vancouver

Nishiyama R, Kagoo T, Ueno H, Yokoyama A. Bortezomib With High-dose Melphalan Conditioning Regimen in Newly Diagnosed Multiple Myeloma Patients: Long-term Follow-up. In Vivo. 2025. doi:10.21873/invivo.13833

BibTeX
@article{Nishiyama2025,
  author = {Nishiyama, Risa and Kagoo, Toshiya and Ueno, Hironori and Yokoyama, Akihiro},
  title = {Bortezomib With High-dose Melphalan Conditioning Regimen in Newly Diagnosed Multiple Myeloma Patients: Long-term Follow-up},
  journal = {In Vivo},
  year = {2025},
  doi = {10.21873/invivo.13833}
}
Kostenlos starten →